EnVivo Pharmaceuticals Announces Progress On Major Drug Programs Focusing On Alzheimer’s, Schizophrenia And Huntington’s Diseases

EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, announced progress on several key programs for addressing Alzheimer’s, Schizophrenia and Huntington’s diseases. EnVivo Pharmaceuticals is developing EVP6124, a selective, orally active Alpha 7 Nicotinic Acetylcholine Receptor Agonist for the treatment of cognitive deficits associated with Alzheimer’s disease and Schizophrenia. [click link for full article]

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on October 20th, 2007